Yesafili Purple Book BLA 761274

BLA number
761274
Proprietary names
Yesafili
Proper names
aflibercept-jbvf
Applicant
Biocon Biologics Inc.
Center
CDER
First observed release
2024-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Yesafiliaflibercept-jbvf351(k) Interchangeable2MG/0.05MLInjectionIntravitrealSingle-Dose VialRxLicensed2024-05-20
002Yesafiliaflibercept-jbvf351(k) Biosimilar2MG/0.05MLInjectionIntravitrealPre-Filled SyringeRxLicensed2026-01-13

Reference Biological Product#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125387Eyleaaflibercept351(a)Rx2026-06-01

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2026-04-01U001Yesafili351(k) InterchangeableRxBiocon Biologics Inc.
2026-01-01N002Yesafili351(k) BiosimilarRxBiocon Biologics Inc.
2024-05-01N001Yesafili351(k) InterchangeableRxBiocon Biologics Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2026-01-01002Yesafili351(k) BiosimilarRxLicensed2026-01-13
2024-05-01001Yesafili351(k) InterchangeableRxLicensed2024-05-20